SOVATELITIDE
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00613691 | Jan 2008 → Jan 2012 | carcinoma | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05514340 | Sep 2023 → Nov 2026 expected | brain hypoxia - ischemia, perinatal asphyxia | Pharmazz, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04054414 | Jan 2019 → Jun 2026 overdue | spinal cord injury | Pharmazz, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04052737 | Mar 2018 → Dec 2022 | Alzheimer disease | Pharmazz, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04046484 | Jan 2018 → Apr 2019 | brain ischemia, stroke disorder | Pharmazz, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01741155 | May 2013 → Jul 2015 | non-small cell lung carcinoma | Spectrum Pharmaceuticals, Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01773785 | Apr 2013 → Sep 2015 | biliary tract cancer | Spectrum Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05691244 | Jul 2025 → Sep 2026 overdue | ischemic stroke | Pharmazz, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT04047563 | Nov 2019 → Feb 2022 | brain ischemia, cerebral infarction | Pharmazz, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05955326 | Jan 2024 → Feb 2026 overdue | brain ischemia | Pharmazz, Inc. | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOVATELITIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3188091 ↗ |
| Known as | IRL-1620 | “Sovateltide is an endothelin B (ETB) receptor agonist (previously used names IRL-1620, SPI-1620 and PMZ-1620; International Non-proprietary Name (INN) approved by WHO is sovateltide).” NCT04054414 ↗3“Sovateltide (PMZ-1620; IRL-1620) is targeted to be used as a "Treatment for hypoxic-ischemic encephalopathy in neonates," which is a life-threatening condition.” NCT05514340 ↗ “Sovateltide (PMZ-1620, IRL-1620) is a highly selective ETB receptor agonist and a synthetic analog of ET-1.” NCT05691244 ↗ “Sovateltide (IRL-1620, PMZ-1620), an endothelin-B receptor agonist” PMID 33428177 ↗ Jan 2021 |
| Known as | PMZ-1620 | “Sovateltide is an endothelin B (ETB) receptor agonist (previously used names IRL-1620, SPI-1620 and PMZ-1620; International Non-proprietary Name (INN) approved by WHO is sovateltide).” NCT04052737 ↗ |
| Known as | Sovateltide | “Sovateltide (IRL-1620, PMZ-1620), an endothelin-B receptor agonist” PMID 33428177 ↗ Jan 20216“PMZ-1620 (sovateltide) is an endothelin-B receptor agonist.” NCT04054414 ↗ |
| Known as | SPI-1620 | “Sovateltide is an endothelin B (ETB) receptor agonist (previously used names IRL-1620, SPI-1620 and PMZ-1620; International Non-proprietary Name (INN) approved by WHO is sovateltide).” NCT04052737 ↗4“Sovateltide is an endothelin B (ETB) receptor agonist (previously used names IRL-1620, SPI-1620 and PMZ-1620; International Non-proprietary Name (INN) approved by WHO is sovateltide).” NCT04054414 ↗ |
| Known as | Tycamzzi | “Sovateltide (Tycamzzi™), an endothelin-B (ET-B) receptor agonist” PMID 39542995 ↗ Nov 2024 |
| Action | Activate | “SPI-1620 an endothelin B agonist” NCT00613691 ↗ |
| Modality | Peptide | “The peptide Sovateltide (IRL-1620) is a highly selective ETB receptor agonist.” NCT04047563 ↗ |
| Route | Intravenous | “SPI-1620 delivered intravenously over one minute on Days 1, 8 and 15” NCT00613691 ↗ |